Vita (PDF, 120 KB) - Studienzentrum Prof. Hanefeld

More documents

Recommendations

Info

Fortbildungen/Wissenschaftliche Tätigkeit Mehrere Poster-Präsentationen/Vorträge zu Tagungen der Deutschen Diabetes Gesellschaft, der ADA (American Diabetes Association) und der EASD (European Association for the Study of Diabetes) Erhalt des Fortbildungszertifikates der Sächsischen Landesärztekammer (gültig bis 2015) Ultraschall-Kurse: Abdomen, Schilddrüse, hirnversorgende Arterien, periphere Arterien Publikationen Glycaemic fluctuations and arrhythmias in type 2 diabetes with cardiovascular disease. Hanefeld M, Stahn A, Henkel E, Teige M, Koehler C, Thomas A. Diabetologia 2012 Vol 55 (Suppl 1) S 102 Relationship between fasting glucose and minimal glucose levels in 24 hours in wellcontrolled patients with type 2 diabetes treated with metformin or insulin glargine Henkel E, Pistrosch F, Schaper F, Koehler C, Hanefeld M. ADA Meeting 2012 Abstract Number : 857-P Association of physical activity with insulin resistance, subclinical inflammation, coagulation, and fibrinolytic biomarkers among population at high risk for type 2 diabetes. Stefanov T, Temelkova-Kurktschiev T, Koehler C, Henkel E, Schaper F, Hanefeld M. Folia Med (Plovdiv). 2012 Apr-Jun;54(2):32-9 Hanefeld M. Fortschritte in der Therapie des Typ 2-Diabetes mit oralen Antidiabetika: Fokus Inkretinkonzept. Henkel E. Leonhardt W,. Die Glukotrias als basis der diagnostik und Therapiekontrolle. Uni-Med Verlag, 2010, 50-60. 2. Auflage Albuminuria and the risk of type 2 diabetes - a prospective study. F. Pistrosch, A. Heidenreich, C. Koehler, E. Henkel, F. Schaper, S. R. Bornstein, M. Hanefeld. ADA Meeting 2010 Abstract Number : 935-P Beziehungen zwischen latenten nächtlichen Hypoglykämien, Nüchternglukose und postprandialen Glukoseverläufen nach einem standardisierten Frühstück bei insulinpflichtigen Typ 2 Diabetikern ermittelt mittels kontinuierlichem interstitiellen Glukosemonitoring. Henkel E, Landgraf M, Hoffmann C, Köhler C, Bilz S; Schoner C, Hanefeld M. Diabetologie und Stoffwechsel 2009; 4: S.49 Relationship between minimal interstitial nocturnal glucose, fasting glucose and maximal glucose in the morning period in type 2 diabetes patients treated with insulin. Henkel E, Landgraf W, Hoffmann C, Köhler C, Hanefeld M. Diabetes (2009); 58 [Suppl1]: 2120-PO Pulse pressure is a strong predictor of cardiovascular risk: Data of the risk factors in impaired glucose tolerance for atherosclerosis and diabetes and the Sofia Metabolic Syndrome studies. Temelkova-Kurktschiev TS, Kurktschiev DP, Vladimirova-Kitova LG, Koehler C, Henkel E, Todorova BR, Schaper F, Fuecker K, Hanefeld M. Folia Med (Plovdiv). 2009 Jan- Mar;51(1):34-41 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. N Engl J Med. 2008 Jun 12;358(24):2560-72. Epub 2008 Jun 6
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S. Diabetes Care. 2008 May;31(5):1007-14. Epub 2008 Feb 11 Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis. Henkel E, Gallo S, Siegert G, Koehler C, Hanefeld M. Blood Coagul Fibrinolysis. 2007 Jun;18(4):327-34 Glucagon is a determinant of fibrinolytic activity in men with normal glucose tolerance, but not in impaired glucose tolerance or type 2 diabetes. Henkel E, Gallo S, Siegert G, Koehler C, M. Hanefeld. ADA Meeting 2006 Abstract Number: 2523-PO Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus. Henkel E, Menschikowski M, Koehler C, Leonhardt W, Hanefeld M. Metabolism. 2005 Sep;54(9):1168-73 Adiponectin Response to Lipid-Glucose Load and Association with PAI-1 and Insulin- Glucose Homeostasis Parameters in Men with Different Stages of Glucose Tolerance. E. Henkel, M. Menschikowski, C. Koehler, W. Leonhardt, M. Hanefeld. ADA Meeting 2004 Abstract Number: 2398-PO Does a lower cut-off limit for impaired fasting glucose change the global cardiovascular risk? Koehler C, Schaper F, Henkel E, Temelkova-Kurktschiev T, Hanefeld M. ADA Meeting 2004 Abstract Number: 1008-P Pulse pressure, an important risk factor for atherosclerosis, increases significantly in subjects with IGT and type 2 Diabetes Mellitus. Temelkova-Kurktschiev T, Koehler C, Henkel E, Hanefeld M. ADA Meeting 2004 Abstract Number: 332-OR Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Stroke. 2004 May;35(5):1073-8. Epub 2004 Apr 8 Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in impaired glucose tolerance for atherosclerosis and diabetes study. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T; Diabetes Care. 2003 Mar;26(3):868-74 Hanefeld M. Fortschritte in der Therapie des Typ 2-diabetes mit oralen Antidiabetika: Gestörte Insulinsekretion im Fokus. Henkel E. Leonhardt W. Die Glukotrias als Basis der Diagnostik und Therapiekontrolle. UNI-MED Verlag 2003, 52-61 Coagulation factor V G allele and HR2 haplotype: factor V activity, activated protein C resistance and risk of venous thrombosis. Kostka H, Schwarz T, Schellong S, Mix C, Kuhlisch E, Temelkova-Kurktschiev T, Henkel E, Köhler C, Gehrisch S, Siegert G. Blood Coagul Fibrinolysis. 2003 Jan;14(1):49-56 M. Hanefeld. Alpha-Glukosidasehemmer- Klinische Anwendung und Prävention des Diabetes mellitus. Henkel E, Pietzsch J. Risikofaktoren- und Stoffwechselkontrolle: Was, wann und wie? 46-60 Uni-Med Verlag 2002
Page 1: Dr. med. Elena Henkel 1978-1984 Stu
Page 5: Postprandial plasma glucose is an i

Vita (PDF, 120 KB) - Studienzentrum Prof. Hanefeld

Create successful ePaper yourself

Delete template?

Save as template?